ATE301722T1 - Integrin-zielvektoren mit transfektionaktivität - Google Patents

Integrin-zielvektoren mit transfektionaktivität

Info

Publication number
ATE301722T1
ATE301722T1 AT98924478T AT98924478T ATE301722T1 AT E301722 T1 ATE301722 T1 AT E301722T1 AT 98924478 T AT98924478 T AT 98924478T AT 98924478 T AT98924478 T AT 98924478T AT E301722 T1 ATE301722 T1 AT E301722T1
Authority
AT
Austria
Prior art keywords
transfection activity
target vectors
integrin target
integrin
nucleic acid
Prior art date
Application number
AT98924478T
Other languages
German (de)
English (en)
Inventor
Stephen Lewis Hart
Original Assignee
Ich Productions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ich Productions Ltd filed Critical Ich Productions Ltd
Application granted granted Critical
Publication of ATE301722T1 publication Critical patent/ATE301722T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electrotherapy Devices (AREA)
AT98924478T 1997-05-29 1998-05-29 Integrin-zielvektoren mit transfektionaktivität ATE301722T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711115.7A GB9711115D0 (en) 1997-05-29 1997-05-29 Integrin-targeting vectors having enhanced transfection activity
PCT/GB1998/001577 WO1998054347A1 (en) 1997-05-29 1998-05-29 Integrin-targeting vectors having transfection activity

Publications (1)

Publication Number Publication Date
ATE301722T1 true ATE301722T1 (de) 2005-08-15

Family

ID=10813246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924478T ATE301722T1 (de) 1997-05-29 1998-05-29 Integrin-zielvektoren mit transfektionaktivität

Country Status (9)

Country Link
US (2) US6458026B1 (cg-RX-API-DMAC7.html)
EP (1) EP1003898B1 (cg-RX-API-DMAC7.html)
JP (1) JP4293292B2 (cg-RX-API-DMAC7.html)
AT (1) ATE301722T1 (cg-RX-API-DMAC7.html)
AU (1) AU7667398A (cg-RX-API-DMAC7.html)
CA (1) CA2288840A1 (cg-RX-API-DMAC7.html)
DE (1) DE69831156T2 (cg-RX-API-DMAC7.html)
GB (1) GB9711115D0 (cg-RX-API-DMAC7.html)
WO (1) WO1998054347A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5043271B2 (ja) 2000-04-12 2012-10-10 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチドベースの化合物
EP1285081A2 (en) * 2000-05-30 2003-02-26 ICH Productions Limited Improved methods of transfection
EP1178117A1 (en) * 2000-08-02 2002-02-06 Erasmus Universiteit Rotterdam Targeting through integrins
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
GB0106315D0 (en) 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
KR100904954B1 (ko) * 2001-05-30 2009-06-26 더 스크립스 리서치 인스티튜트 핵산용 전달 시스템
CN1622830A (zh) 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0210538D0 (en) * 2002-05-08 2002-06-19 Univ London Lipids and gene delivery
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
KR20060015534A (ko) * 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
AU2004297533B2 (en) 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
MX2008009970A (es) * 2006-02-01 2008-11-19 Univ Johns Hopkins Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos.
US10034674B2 (en) * 2006-02-02 2018-07-31 Steven C Chudik Universal anterior cruciate ligament repair and reconstruction system
GB0610636D0 (en) 2006-05-30 2006-07-05 Univ London Materials and complexes for the delivery of biologically-active material to cells
EP2178896A1 (en) * 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
WO2009094634A1 (en) 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
JP2012513589A (ja) 2008-12-23 2012-06-14 ジーイー・ヘルスケア・リミテッド 骨髄イメージング剤としての99mTc−ペプチド系化合物の応用
EP4710943A3 (en) 2015-08-28 2026-04-29 Molecular Transfer, Inc. Transfection complexes and methods of using the same
WO2017151733A1 (en) 2016-03-01 2017-09-08 Molecular Transfer, Inc. Plant virus movement proteins and methods of using the same
GB201604235D0 (en) 2016-03-11 2016-04-27 Ucl Business Plc Lipids and complexes for the delivery of biologically-active material to cells
GB201803419D0 (en) * 2018-03-02 2018-04-18 Ucl Business Plc Complex for the delivery of cas9 proteins guide RNA to cells
US12649000B2 (en) 2018-03-19 2026-06-09 Algipharma As Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
DE69536153D1 (de) 1994-11-17 2011-05-05 Ich Productions Ltd Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors
WO1996040961A1 (en) 1995-06-07 1996-12-19 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery

Also Published As

Publication number Publication date
EP1003898B1 (en) 2005-08-10
CA2288840A1 (en) 1998-12-03
DE69831156T2 (de) 2006-06-08
DE69831156D1 (de) 2005-09-15
US6458026B1 (en) 2002-10-01
GB9711115D0 (en) 1997-07-23
JP4293292B2 (ja) 2009-07-08
EP1003898A1 (en) 2000-05-31
US20020042384A1 (en) 2002-04-11
WO1998054347A1 (en) 1998-12-03
AU7667398A (en) 1998-12-30
US20030013644A1 (en) 2003-01-16
JP2002502243A (ja) 2002-01-22

Similar Documents

Publication Publication Date Title
DE69831156D1 (de) Integrin-zielvektoren mit transfektionaktivität
CA2166931A1 (en) Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon
AU7703598A (en) Generation and delivery of travel-related, location-sensitive information
BR9612677A (pt) Sistemas complementares de vetores adenovírais e linhagens celulares
ZA971159B (en) Target cell-specific vectors for inserting genes into cells, pharmaceuticals comprising such vectors and their use.
EP1019028A4 (en) $ I PROTEIN (CHLAMYDIA), GENE SEQUENCE, AND USES THEREOF
AU5671096A (en) Methods, nucleotide sequences and host cells for assaying ex ogenous and endogenous protease activity
EP0981874A4 (en) OPTIMALLY OPERATIONAL, PROACTIVE CRYPTOSYSTEM WITH PUBLIC KEY AND RELATED METHOD
ZA983930B (en) Excitatory amino acid receptor modulators.
DE69333766D1 (de) Herstellung von phytat-degradierenden enzymen in trichoderma
PT1166775E (pt) Distribuição génica lipossomal direccionada
EP0892048A3 (en) XAF genes and polypeptides and their use for modulating apoptosis
EP1044444A4 (en) BUSINESS CARD WITH DETACHABLE LABELS
CA2281206A1 (en) Geranyl diphosphate synthase genes
GB9724143D0 (en) Pharmaceutical conjugate
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
CA2014948A1 (en) Genes coding for a protein having human macif activity, expression vectors containing said genes, transformant cells and proteins having human macif activity
DE59504918D1 (de) Direktziehendes haarfärbemittel
FI971377L (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
EP0970192A4 (en) NUCLEIC ACID CODING THE ALGU PROTEIN OF M. TUBERCULOSIS.
NZ334744A (en) Method for determining expression of aberrant forms of APC protein
WO2001000799A8 (fr) Nouvelle proteine et son adn
WO1998054344A3 (en) Modulators of morphogen expression and methods of identifying the same
AU4121997A (en) Method for sorting antifungal molecules acting on the glucanosyltransferase activity
WO1996038556A3 (fr) Deltap62, ses variants, sequences d'acides nucleiques les codant, et leurs utilisations en therapie genique anti-cancereuse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties